Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 1

Conditions

Myeloproliferative Disorders 5Myelodysplastic Syndromes 5Primary Myelofibrosis 4Anemia 4beta-Thalassemia 2Leukemia, Myeloid, Acute 2Thrombocytosis 1Higher-risk Myelodysplastic Syndrome 1Hematologic Neoplasms 1Granulosa cell tumor of the ovary 1

Interventions

Cyclophosphamide 3thymoglobulin 2luspatercept 2fludarabine 2Rituximab 2Melphalan 2Busulfan 2fludarabine phosphate 1Whole-Body Irradiation 1Thiotepa 1Tacrolimus 1Sugammadex 1Mycophenolic Acid 1Levetiracetam 1Dexamethasone 1Bortezomib 1Antilymphocyte Serum 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
beta-Thalassemia × luspatercept × Clear all
NCT04064060 2026-05-28

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Celgene

Phase 3 Recruiting
665 enrolled
Myeloid

Myelodysplastic Syndromes, Myeloproliferative Disorders, beta-Thalassemia

NCT02604433 2023-04-18

BELIEVE

Celgene

Phase 3 Completed
336 enrolled 38 charts 1 FDA

beta-Thalassemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡